Immune profiling of cancer patients treated with immunotherapy: Advances and challenges

Lorenzo Pilla, Cristina Maccalli

Research output: Contribution to journalReview article

3 Citations (Scopus)

Abstract

The recent advances in immunotherapy and the availability of novel drugs to target the tumor microenvironment have dramatically changed the paradigm of cancer treatment. Nevertheless, a significant proportion of cancer patients are unresponsive or develop resistance to these treatments. With the aim to increase the clinical efficacy of immunotherapy, combinations of agents and standard therapies with complementary actions have been developed mostly on an empirical base, since their mechanisms of actions are not yet fully dissected. The characterization of immune responsiveness and its monitoring along with the treatment of cancer patients with immunotherapy can provide insights into the mechanisms of action of these therapeutic regimens and contribute to the optimization of patients' stratification and of combination strategies and to the prediction of treatment-related toxicities. Thus far, none of the immunomonitoring strategies has been validated for routine clinical practice. Moreover, it is becoming clear that the genomic and molecular make-up of tumors and of the infiltrating immune system represent important determinants of the clinical responses to immunotherapy. This review provides an overview of different approaches for the immune profiling of cancer patients and discusses their advantages and limitations. Recent advances in genomic-based assays and in the identification of host genomic relationships with immune responses represent promising approaches to identify molecular determinants and biomarkers to improve the clinical efficacy of cancer immunotherapy.

Original languageEnglish
Article number76
JournalBiomedicines
Volume6
Issue number3
DOIs
Publication statusPublished - 1 Sep 2018

Fingerprint

Immunotherapy
Tumors
Oncology
Immune system
Biomarkers
Toxicity
Assays
Neoplasms
Availability
Monitoring
Pharmaceutical Preparations
Therapeutics
Tumor Microenvironment
Complementary Therapies
Immune System

Keywords

  • Genomic determinants
  • Immune monitoring
  • Immunotherapy
  • Soluble markers
  • T cell responses

ASJC Scopus subject areas

  • Medicine (miscellaneous)
  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Immune profiling of cancer patients treated with immunotherapy : Advances and challenges. / Pilla, Lorenzo; Maccalli, Cristina.

In: Biomedicines, Vol. 6, No. 3, 76, 01.09.2018.

Research output: Contribution to journalReview article

@article{a5f0ada465b549d7a744c73f40448ee5,
title = "Immune profiling of cancer patients treated with immunotherapy: Advances and challenges",
abstract = "The recent advances in immunotherapy and the availability of novel drugs to target the tumor microenvironment have dramatically changed the paradigm of cancer treatment. Nevertheless, a significant proportion of cancer patients are unresponsive or develop resistance to these treatments. With the aim to increase the clinical efficacy of immunotherapy, combinations of agents and standard therapies with complementary actions have been developed mostly on an empirical base, since their mechanisms of actions are not yet fully dissected. The characterization of immune responsiveness and its monitoring along with the treatment of cancer patients with immunotherapy can provide insights into the mechanisms of action of these therapeutic regimens and contribute to the optimization of patients' stratification and of combination strategies and to the prediction of treatment-related toxicities. Thus far, none of the immunomonitoring strategies has been validated for routine clinical practice. Moreover, it is becoming clear that the genomic and molecular make-up of tumors and of the infiltrating immune system represent important determinants of the clinical responses to immunotherapy. This review provides an overview of different approaches for the immune profiling of cancer patients and discusses their advantages and limitations. Recent advances in genomic-based assays and in the identification of host genomic relationships with immune responses represent promising approaches to identify molecular determinants and biomarkers to improve the clinical efficacy of cancer immunotherapy.",
keywords = "Genomic determinants, Immune monitoring, Immunotherapy, Soluble markers, T cell responses",
author = "Lorenzo Pilla and Cristina Maccalli",
year = "2018",
month = "9",
day = "1",
doi = "10.3390/biomedicines6030076",
language = "English",
volume = "6",
journal = "Biomedicines",
issn = "2227-9059",
publisher = "MDPI AG",
number = "3",

}

TY - JOUR

T1 - Immune profiling of cancer patients treated with immunotherapy

T2 - Advances and challenges

AU - Pilla, Lorenzo

AU - Maccalli, Cristina

PY - 2018/9/1

Y1 - 2018/9/1

N2 - The recent advances in immunotherapy and the availability of novel drugs to target the tumor microenvironment have dramatically changed the paradigm of cancer treatment. Nevertheless, a significant proportion of cancer patients are unresponsive or develop resistance to these treatments. With the aim to increase the clinical efficacy of immunotherapy, combinations of agents and standard therapies with complementary actions have been developed mostly on an empirical base, since their mechanisms of actions are not yet fully dissected. The characterization of immune responsiveness and its monitoring along with the treatment of cancer patients with immunotherapy can provide insights into the mechanisms of action of these therapeutic regimens and contribute to the optimization of patients' stratification and of combination strategies and to the prediction of treatment-related toxicities. Thus far, none of the immunomonitoring strategies has been validated for routine clinical practice. Moreover, it is becoming clear that the genomic and molecular make-up of tumors and of the infiltrating immune system represent important determinants of the clinical responses to immunotherapy. This review provides an overview of different approaches for the immune profiling of cancer patients and discusses their advantages and limitations. Recent advances in genomic-based assays and in the identification of host genomic relationships with immune responses represent promising approaches to identify molecular determinants and biomarkers to improve the clinical efficacy of cancer immunotherapy.

AB - The recent advances in immunotherapy and the availability of novel drugs to target the tumor microenvironment have dramatically changed the paradigm of cancer treatment. Nevertheless, a significant proportion of cancer patients are unresponsive or develop resistance to these treatments. With the aim to increase the clinical efficacy of immunotherapy, combinations of agents and standard therapies with complementary actions have been developed mostly on an empirical base, since their mechanisms of actions are not yet fully dissected. The characterization of immune responsiveness and its monitoring along with the treatment of cancer patients with immunotherapy can provide insights into the mechanisms of action of these therapeutic regimens and contribute to the optimization of patients' stratification and of combination strategies and to the prediction of treatment-related toxicities. Thus far, none of the immunomonitoring strategies has been validated for routine clinical practice. Moreover, it is becoming clear that the genomic and molecular make-up of tumors and of the infiltrating immune system represent important determinants of the clinical responses to immunotherapy. This review provides an overview of different approaches for the immune profiling of cancer patients and discusses their advantages and limitations. Recent advances in genomic-based assays and in the identification of host genomic relationships with immune responses represent promising approaches to identify molecular determinants and biomarkers to improve the clinical efficacy of cancer immunotherapy.

KW - Genomic determinants

KW - Immune monitoring

KW - Immunotherapy

KW - Soluble markers

KW - T cell responses

UR - http://www.scopus.com/inward/record.url?scp=85063340713&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85063340713&partnerID=8YFLogxK

U2 - 10.3390/biomedicines6030076

DO - 10.3390/biomedicines6030076

M3 - Review article

AN - SCOPUS:85063340713

VL - 6

JO - Biomedicines

JF - Biomedicines

SN - 2227-9059

IS - 3

M1 - 76

ER -